SCHEMBL672223

SCHEMBL672223

Nc1ncnc2cc(OCc3ccc(F)c(Cl)c3)c(OCCCN3CCOCC3)cc12

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 17/20 0.62
KDR P35968 4/20 0.62
ERBB2 P04626 4/20 0.62
FLT4 P35916 2/20 0.62
BRAF P15056 2/20 0.62
CIT O14578 2/20 0.62
GAK O14976 2/20 0.62
EPHB6 O15197 2/20 0.62
RIPK2 O43353 2/20 0.62
STK17B O94768 2/20 0.62
STK10 O94804 2/20 0.62
ABL1 P00519 2/20 0.62
LCK P06239 2/20 0.62
LYN P07948 2/20 0.62
RET P07949 2/20 0.62
MET P08581 2/20 0.62
HCK P08631 2/20 0.62
FGR P09769 2/20 0.62
KIT P10721 2/20 0.62
SRC P12931 2/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31491127 0.83 SRC (0.53) EGFRKDRERBB2FLT4BRAF
SCHEMBL13319080 0.81 EGFR (0.71) EGFRKDRERBB2FLT4BRAF
SCHEMBL4422710 0.80 SRC (0.65) EGFRKDRERBB2FLT4BRAF
SCHEMBL29540227 0.80 SRC (0.65) EGFRKDRERBB2FLT4BRAF
SCHEMBL4428694 0.80 SRC (0.65) EGFRKDRERBB2FLT4BRAF
SCHEMBL28713534 0.80 EGFR (0.92) EGFRKDRERBB2FLT4BRAF
SCHEMBL29577833 0.80 EGFR (0.92) EGFRKDRERBB2FLT4BRAF
SCHEMBL28969386 0.79 SRC (0.50) EGFRKDRERBB2FLT4BRAF
SCHEMBL19612073 0.79 EGFR (0.86) EGFRKDRERBB2FLT4BRAF
SCHEMBL4597943 0.79 EGFR (0.66) EGFRKDRERBB2CITGAK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2605650-A2 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED HEXITOLS SUCH AS DIANHYDROGALACTITOL AND DIACETYLDIANHYDROGALACTITOL Del Mar Pharmaceuticals (CA) 2013-06-26 EP disclosed
WO-2012024367-A2 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED HEXITOLS SUCH AS DIANHYDROGALACTITOL AND DIACETYLDIANHYDROGALACTITOL DEL MAR PHARMACEUTICALS (CA) 2012-02-23 WO disclosed